Press Releases

Press Releases

January 7, 2020
WOBURN, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will
Displaying 11 - 12 of 12